All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Clinical trials offer patients with multiple myeloma (MM) treatment options that would otherwise be unavailable, and determine the future of MM approved drug regimens. However, there is a gap between the efficacy of a treatment in a clinical trial setting and the effectiveness it provides in real-world clinical practice. Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, and collaborators, examined the possible reasons behind this apparent discrepancy focusing on patients with relapsed/refractory (R/R) MM, and presented their findings in Blood Cancer Journal in November 2018.
Conclusions
Direct comparisons across clinical trials and between clinical trials and real-world outcomes are challenging. A wide range of factors inhibits immediate translation of the efficacy of a drug regimen from the clinical trial environment to an effective treatment in clinical practice. A way around this issue is by using indirect comparisons of relative efficacy versus a common comparator with the implementation of hazard ratios.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?